Barbexaclone

DB09001ExperimentalSmall molecule

Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties... Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine.

Mechanism: Phenobarbitol targets GABA receptors in the CNS. Propylhexedrine is a TAAR1 agonist.
Curator reviewed
Primary indication: Created for the treatment for epilepsy, with the intent of creating an antiepileptic with less sedative properties than phenobarbital.Curator reviewed
Formula / weight: C₂₂H₃₃N₃O₃ · 387.524 g/mol (avg)
Code names: Su 42

Resolves to

Compound

UNII291GX1YB65CAS4388-82-3PubChem71196

Clinical / RWD

RxNorm46795ATCN03AA04

Structure

InChIKeyMJCBWPMBFCUHBP-NPULLEENSA-NSMILESCN[C@@H](C)CC1CCCCC1.CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1

What you can answer from here — as of February 21, 2021

1,143Drug interactionsStructured to mechanism, not free text

2Marketed productsAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 11 drug categories

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of Barbexaclone, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account